Webinars
Educational and engaging virtual presentations on current biopharmaceutical topics
Upcoming Webinars
We are currently planning the next webinar. Please check back for updates or subscribe to our blog by providing your e-mail to be notified directly.
On-Demand Webinars
A list of Chamow & Associates’ archived webinar recordings by most recent presentation date, available 24/7 for viewing at your convenience.
Impact of COVID-19 on Clinical Biomanufacturing and Supply Chains Digital Brief
Presented on January 20, 2020 by Dr. Steven Chamow
Vaccine development typically occurs in stages, and it takes years to develop the end product. During a pandemic, this timeline is fast-tracked significantly, but how feasible is it to scale up vaccine distribution across the globe quickly and effectively? In this interactive digital brief, the following topics are covered:
- Overview of leading COVID vaccine programs
- COVID-19 versus other clinical development programs
- Outsourcing in biomanufacturing
- Near-term impact, including CDMOs, other services, and supply chains
- Long-term impacts, including:
- More facilities with increased investment
- Expansions of single use and more modular facilities
- Better inventory management and more supply chain oversight
- Faster R&D and speed-to-market
- Q&A, discussion, and networking
- Steve Banker, “It Isn’t Just About a COVID Vaccine, There Are Significant Supply Chain Hurdles”, Forbes, 9 Nov 2020
- Brooke Sutherland, “Vaccine Supply Chains Bend But Don’t Break”, Bloomberg Opinion, 4 Dec 2020
- Jonathan Gardner, Ned Pagliarulo and Ben Fidler, “The First Coronavirus Vaccines Have Arrived. Here’s Where the Rest Stand.” BiopharmaDive, 14 Jan 2021
CDMO Selection for Bispecific Antibody Development: A Case Study Matching Capability to Need
Presented on December 1, 2020 by Dr. Steven Chamow and Tracy Kinjerski
Selecting a CDMO for bispecific antibody development can be a challenging affair. What is the CDMO selection process and how can a company best match capability to need? The following topics are covered in this webinar:
- Common challenges associated with CDMO selection
- Solutions and tools including Target Product Profiles for CDMO evaluation
- Scope of work from development to IND
- Judy Meyers, How to Find the Right CDMO Partner in Pharma, Pharma Manufacturing, Oct, 2019
- Stephen Closs, Quality by Design: Working With Your Contract Manufacturer, Chemistry Today 32, 10-13 (2014)
- David Wilkerson, Outsourcing in Pharma and Biotech: Shifting to Contract Manufacturing and Development, Zymewire blog, 4 Mar 2020
Developing Therapeutic Monoclonal Antibodies at Pandemic Pace
Presented on August 25, 2020 by Darlene Rosario and Dr. Steven Chamow
This webinar addresses how the speed of CMC development can be optimized to meet the current public health emergency and whether therapeutic mAbs can be developed safely at pandemic pace. The following topics are covered:
- Potential sources of drugs for COVID-19
- The biology of COVID-19
- Potential opportunities to accelerate a mAb CMC development timeline
- Current leading therapeutic programs
- Jon Cohen, Antibodies May Curb Pandemic Before Vaccines, Science, 14 Aug 2020
- Brian Kelley, Developing Therapeutic Monoclonal Antibodies at Pandemic Pace, Nature Biotechnology vol. 38, May 2020
- Paul Tullis, How a Potential Treatment for the Coronavirus Turned Up in a Scientist’s Freezer, New Yorker, 20 Jul 2020
What Does it Take to Develop a New Drug for COVID-19: Session 2 | Technologies for New Vaccines
Presented on June 30, 2020 by Dr. Steven Chamow
The pandemic caused by the novel coronavirus has had an unprecedented impact on our lives. What is COVID-19 and what does it take to develop a new drug to combat it? This is the second session of a two-part webinar. This webinar is designed for the general public to better understand the novel coronavirus that is impacting our world and what it will take to treat it. The following topics are covered:
- The biology behind coronavirus and COVID-19
- The current drug development process in the United States
- The tools and actions needed to develop a new drug for COVID-19
What Does it Take to Develop a New Drug for COVID-19: Session 1
Presented on June 23, 2020 by Dr. Steven Chamow
The pandemic caused by the novel coronavirus has had an unprecedented impact on our lives. What is COVID-19 and what does it take to develop a new drug to combat it? This is the first session of a two-part webinar. This two-part webinar is designed for the general public to better understand the novel coronavirus that is impacting our world and what it will take to treat it. The following topics are covered:
- The biology behind coronavirus and COVID-19
- The current drug development process in the United States
- The tools and actions needed to develop a new drug for COVID-19
Suggested pre-read articles (Click to view):
- “Promoting Safe and Effective Drugs for 100 Years” by Michelle Meadows. Published in 2006 to commemorate the centennial anniversary of FDA, this article from the FDA History Office traces the evolution of FDA’s role as a regulatory agency. In particular, it highlights milestone legislation that transformed the agency into what it is today.
- “COVID-19 Treatment Might Already Exist in Old Drugs-We’re Using Pieces of the Coronavirus Itself to Find Them” by Nevan Krogan, PhD. Written by a UCSF researcher, this article which was published in March 2020 gives a clear understanding of how the SARS-CoV-2 virus infects cells. Dr. Krogan outlines his group’s strategy for finding new drugs to treat it.